Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Educational use only. This page aggregates publicly reported US prices for educational comparison. Peptides.NYC sells nothing and endorses no vendor. Prices change frequently; every figure below is dated and sourced — verify the current price before making any decision, and consult a licensed healthcare provider.
GLP-1 and peptide prices: the dollars-per-milligram index
The Peptides.NYC Price-Per-Mg Index normalizes the cost of GLP-1 medications to a single comparable metric — dollars per milligram — using publicly reported US prices. Brand GLP-1s list at roughly $18.00–$140.52 per mg depending on the molecule, while manufacturer self-pay programs cut that to $11.65–$62.38. Every figure is dated, sourced, and computed from the dose inputs shown beside it.
Quick answer
Brand GLP-1s list at roughly $18.00–$140.52 per milligram — tirzepatide is cheapest per mg because its maintenance dose is large, while brand semaglutide is priciest. Manufacturer self-pay programs run $11.65–$62.38 per mg. Dollars-per-mg compares cost, not clinical effect.
At a glance
- Most expensive per mg: brand semaglutide at list price ($140.52/mg).
- Cheapest brand option: manufacturer self-pay, at roughly $11.65–$62.38/mg — the low end is a Zepbound KwikPen at its top maintenance dose, the high end an Ozempic pen. Self-pay is priced as a per-dose ladder that flattens at the top — Lilly charges the same $699 a month at 10, 12.5 and 15 mg — so the highest maintenance dose is the cheapest per mg, while the rungs below it do not fall in a straight line. The 2.5 mg starting dose is excluded from that range because Lilly states it is not an approved maintenance dose.
- Tirzepatide is far cheaper per mg than semaglutide because maintenance doses are larger (10–15 mg/wk vs 2.4 mg/wk) — a key reason raw "$/month" comparisons mislead.
- Compounded and telehealth semaglutide and tirzepatide cluster around $99–$449/month, though the FDA’s 2025 shortage resolution sharply curtailed routine GLP-1 compounding (see our Semaglutide Compounding Ban 2026 explainer).
- Two products have no published list price at all: Lilly publishes none for Zepbound, and NovoCare publishes none for Rybelsus. We quote no number for either rather than repeat a third-party figure.
- Research-market compounds (BPC-157, TB-500, GHK-Cu and others) carry no prices on this page yet — we have not run a first-party survey, and we do not reproduce figures from third-party buying guides (see how to verify peptide purity).
Why dollars-per-mg (and why "$/month" misleads)
A "$1,000/month" headline tells you almost nothing without the dose. Wegovy’s 2.4 mg weekly maintenance is about 9.6 mg a month; Zepbound’s 15 mg weekly is about 60 mg a month. Same ballpark monthly price, 6× difference in milligrams. Normalizing to $/mg is the only apples-to-apples way to compare across molecules — though it is not a measure of clinical equivalence, since different peptides do different things at different doses. Use $/mg for cost transparency, not as medical guidance.
Method
- $/mg computation: every dollars-per-milligram figure on this page is computed, never typed. The formula is
price ÷ (mg per dose × doses per period), using the dose inputs printed beside each row. Weekly injectables are counted at four doses a month; daily orals at thirty. Nothing on this page carries a $/mg we cannot reproduce from its own inputs. - Sources: manufacturer list prices, published wholesale acquisition cost, manufacturer self-pay programs, and compounding/telehealth program rates — each linked on the row it supports.
- Research-market compounds: no figures are published. The prices that used to appear here were transcribed from third-party buying guides rather than measured by us, so they have been withdrawn. Ranges will appear only after a documented first-party survey that can state its method, its date and how many sellers it covered.
- Recency: the newest figure on this page is dated 2026-09-30, and every row carries its own date; some are older, and a wholesale price that has not changed since 2025 is dated 2025. Prices — especially compounded and telehealth — change frequently; treat them as a snapshot, not a quote.
- List price is not net price. These are what a cash payer faces, not what the health system pays. A 2025 cost-effectiveness analysis in JAMA Health Forum estimated the net annual price of tirzepatide at roughly $6,236 and semaglutide at roughly $8,412 after rebates (Hwang et al., 2025).
- Independence: Peptides.NYC has no affiliate relationship with any product or pharmacy listed and sells nothing.
Brand GLP-1 list, WAC and self-pay prices
List price, wholesale acquisition cost and manufacturer self-pay are three different numbers for the same box, and mixing them is how price comparisons go wrong. Each row says which one it is.
| Product | Price type | Price | Per milligram | As of | Notes and sources |
|---|---|---|---|---|---|
| Ozempic (semaglutide injection)2 mg pen | Manufacturer list | $1,027.51 per month | $128.44 | 2026-09-16 | A lower figure, $997.58, also circulates and appears further down NovoCare’s pages. We do not use it: the list-price page itself does not support it.Ozempic® (semaglutide) injection 0.5 mg, 1 mg, 2 mg List Price & Insurance Coverage Explained | NovoCare® |
| Ozempic (semaglutide injection)2 mg pen | Manufacturer self-pay | $499 per month | $62.38 | 2026-09-16 | NovoCare self-pay at the 2 mg dose. The same page states $349/mo for the 0.25 mg, 0.5 mg and 1 mg doses, and an introductory $199 for two monthly fills of 0.25/0.5 mg through 2026-12-31.Save on Ozempic® | NovoCare® |
| Wegovy (semaglutide injection)2.4 mg maintenance dose | Manufacturer list | $1,349.02 per month | $140.52 | 2026-09-16 | Wegovy® (semaglutide) injection list price and coverage | NovoCare® |
| Wegovy (semaglutide injection)2.4 mg maintenance dose | Manufacturer self-pay | $349 per month | $36.35 | 2025-11-17 | Self-pay, all doses. An introductory $199/mo covers the first two months at 0.25/0.5 mg; the HD 7.2 mg pen is $399/mo. This replaced a $499/mo self-pay price on 2025-11-17.Save on Wegovy® | Wegovy.comNovo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 per month |
| Mounjaro (tirzepatide injection)pack of four pens, 15 mg maintenance dose | Wholesale acquisition cost | $1,079.77 per pack | $18.00 | 2025-01-02 | Identical across all strengths, which is why tirzepatide is cheap per mg: the pack price does not rise with the dose. This is the closest published list-side tirzepatide benchmark, since Lilly publishes no Zepbound list price; the KwikPen self-pay rows below are a different kind of price, not a list price.Lilly WAC disclosure (Colorado) |
| Zepbound (tirzepatide injection)prefilled pen, 15 mg maintenance dose | Manufacturer list | No published price. No list price published. Lilly states only that savings are capped at wholesale acquisition cost minus $499. Third-party figures conflict, so we quote none — use the Mounjaro WAC row as the closest published tirzepatide list price. This is the single-dose Pen; the KwikPen rows below carry a published self-pay price, which is a different thing. | No price to compute from | 2026-09-16 | Zepbound® coverage and savings | Lilly |
| Zepbound (tirzepatide)single-patient-use KwikPen, 2.5 mg per weekly dose | Manufacturer self-pay | $299 per month | $29.90Not comparable to injectable figures | 2026-09-30 | Regular self-pay price, quoted verbatim from the Purchase Offer Terms: “Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg.” Lilly defines the month on this ladder as “28-days and up to 1 single-patient-use KwikPen”; a 28-day month is exactly four weekly doses, so the four doses per month this row computes from are exact here rather than the calendar-month approximation used elsewhere on the page. Lilly states on this page that “2.5 mg is a starting dose and is not approved as a maintenance dose”, so the per-mg figure here is the cost of a titration month, not of ongoing treatment. Flagged not comparable for that reason: it would otherwise sit in the same range as maintenance doses and read as an ongoing price.Zepbound® coverage and savings | Lilly |
| Zepbound (tirzepatide)single-patient-use KwikPen, 5 mg per weekly dose | Manufacturer self-pay | $399 per month | $19.95 | 2026-09-30 | Regular self-pay price, quoted verbatim from the Purchase Offer Terms: “Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg.” Lilly defines the month on this ladder as “28-days and up to 1 single-patient-use KwikPen”; a 28-day month is exactly four weekly doses, so the four doses per month this row computes from are exact here rather than the calendar-month approximation used elsewhere on the page.Zepbound® coverage and savings | Lilly |
| Zepbound (tirzepatide)single-patient-use KwikPen, 7.5 mg per weekly dose | Manufacturer self-pay | $499 per month | $16.63 | 2026-09-30 | Regular self-pay price, quoted verbatim from the Purchase Offer Terms: “Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg.” Lilly defines the month on this ladder as “28-days and up to 1 single-patient-use KwikPen”; a 28-day month is exactly four weekly doses, so the four doses per month this row computes from are exact here rather than the calendar-month approximation used elsewhere on the page. Lilly also runs a purchase offer that lowers this dose to $449, applied automatically on a first purchase and held only if each refill is bought within 45 days. Lilly states the offer is “valid for 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses”, so it reaches this dose but not the $299 and $399 rungs, where the regular price is already lower. The Purchase Offer Terms state no expiry of their own; the card that carries the offer expires 2026-12-31. The row carries the regular price rather than the offer, which is how the Wegovy self-pay row treats its $199 introductory tier.Zepbound® coverage and savings | Lilly |
| Zepbound (tirzepatide)single-patient-use KwikPen, 10 mg per weekly dose | Manufacturer self-pay | $699 per month | $17.48 | 2026-09-30 | Regular self-pay price, quoted verbatim from the Purchase Offer Terms: “Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg.” Lilly defines the month on this ladder as “28-days and up to 1 single-patient-use KwikPen”; a 28-day month is exactly four weekly doses, so the four doses per month this row computes from are exact here rather than the calendar-month approximation used elsewhere on the page. Lilly also runs a purchase offer that lowers this dose to $449, applied automatically on a first purchase and held only if each refill is bought within 45 days. Lilly states the offer is “valid for 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses”, so it reaches this dose but not the $299 and $399 rungs, where the regular price is already lower. The Purchase Offer Terms state no expiry of their own; the card that carries the offer expires 2026-12-31. The row carries the regular price rather than the offer, which is how the Wegovy self-pay row treats its $199 introductory tier.Zepbound® coverage and savings | Lilly |
| Zepbound (tirzepatide)single-patient-use KwikPen, 12.5 mg per weekly dose | Manufacturer self-pay | $699 per month | $13.98 | 2026-09-30 | Regular self-pay price, quoted verbatim from the Purchase Offer Terms: “Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg.” Lilly defines the month on this ladder as “28-days and up to 1 single-patient-use KwikPen”; a 28-day month is exactly four weekly doses, so the four doses per month this row computes from are exact here rather than the calendar-month approximation used elsewhere on the page. Lilly also runs a purchase offer that lowers this dose to $449, applied automatically on a first purchase and held only if each refill is bought within 45 days. Lilly states the offer is “valid for 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses”, so it reaches this dose but not the $299 and $399 rungs, where the regular price is already lower. The Purchase Offer Terms state no expiry of their own; the card that carries the offer expires 2026-12-31. The row carries the regular price rather than the offer, which is how the Wegovy self-pay row treats its $199 introductory tier.Zepbound® coverage and savings | Lilly |
| Zepbound (tirzepatide)single-patient-use KwikPen, 15 mg per weekly dose | Manufacturer self-pay | $699 per month | $11.65 | 2026-09-30 | Regular self-pay price, quoted verbatim from the Purchase Offer Terms: “Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg.” Lilly defines the month on this ladder as “28-days and up to 1 single-patient-use KwikPen”; a 28-day month is exactly four weekly doses, so the four doses per month this row computes from are exact here rather than the calendar-month approximation used elsewhere on the page. Lilly also runs a purchase offer that lowers this dose to $449, applied automatically on a first purchase and held only if each refill is bought within 45 days. Lilly states the offer is “valid for 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses”, so it reaches this dose but not the $299 and $399 rungs, where the regular price is already lower. The Purchase Offer Terms state no expiry of their own; the card that carries the offer expires 2026-12-31. The row carries the regular price rather than the offer, which is how the Wegovy self-pay row treats its $199 introductory tier.Zepbound® coverage and savings | Lilly |
| Rybelsus (oral semaglutide tablet)14 mg daily | Manufacturer list | No published price. No list price published on NovoCare. The Rybelsus page carries no dollar figure (retrieved September 2026), and the $997.58 that circulates is not on it. For published oral semaglutide pricing, see the Ozempic tablets row. | No price to compute from | 2026-09-16 | RYBELSUS® (semaglutide) tablets 7 mg or 14 mg Savings & Support Resources | NovoCare®Ozempic® (semaglutide) injection 0.5 mg, 1 mg, 2 mg List Price & Insurance Coverage Explained | NovoCare® |
| Ozempic tablets (oral semaglutide)9 mg tablet daily | Manufacturer list | $1,027.51 per month | $3.81Not comparable to injectable figures | 2026-09-16 | Oral bioavailability is far lower, so the daily milligram dose is much larger. The per-mg figure is not comparable to an injectable.Ozempic® (semaglutide) injection 0.5 mg, 1 mg, 2 mg List Price & Insurance Coverage Explained | NovoCare® |
| Oral Wegovy (oral semaglutide tablet)25 mg tablet daily | Manufacturer self-pay | $299 per month | $0.399Not comparable to injectable figures | 2026-09-30 | Manufacturer self-pay ladder for the tablet, per NovoCare: $149/mo at 1.5 mg, $199/mo at 4 mg, $299/mo at 9 mg and 25 mg. A previous version of this note put the 4 mg dose at $149; the manufacturer states $199. Oral, so not comparable to an injectable per-mg figure.Wegovy® (semaglutide) injection list price and coverage | NovoCare®GoodRx to Match Novo Nordisk Price for Oral Semaglutide | AJMC |
Compounded and telehealth GLP-1 prices
These are program prices, not drug prices: most bundle or separate a membership fee, and many do not publish the dose they dispense, which is why several rows carry no $/mg.
| Product | Price type | Price | Per milligram | As of | Notes and sources |
|---|---|---|---|---|---|
| Compounded semaglutide (injectable)telehealth program | Telehealth / compounded cash price | $199–$299 per month | Dose not published | 2026-06-01Carried over, not re-checked | $199/mo on an annual plan to $299/mo month-to-month. Program largely discontinued after the 2025 shortage resolution. Dose is not published per plan, so no per-mg figure is computable.Compounded Semaglutide (Injectable) | Hims support |
| Compounded semaglutide (oral pill)telehealth program | Telehealth / compounded cash price | $99 per month | Dose not published | 2026-06-01Carried over, not re-checked | $49 for the first month, $99/mo standard. Withdrawn after the Novo Nordisk settlement.Hims & Hers newsroom |
| Compounded semaglutide (injectable)telehealth program | Telehealth / compounded cash price | $149–$299 per month | Dose not published | 2026-06-01Carried over, not re-checked | Plan-dependent. Compounding is now limited to documented medical need.How much does semaglutide cost? | Ro |
| Compounded semaglutide (injectable)telehealth program, medication only | Telehealth / compounded cash price | $279 per month | Dose not published | 2026-06-01Carried over, not re-checked | Billed $837 per 12 weeks, plus a separate $149/mo telehealth fee.Noom Med pricing |
| Compounded semaglutide (injectable)compounding program, medication only | Telehealth / compounded cash price | $99 per month | $10.31 | 2026-06-01Carried over, not re-checked | Flat across doses, which is what makes the per-mg figure computable. A $79/mo membership brings the all-in cost to $178/mo; the per-mg figure is medication only.Mochi Health review (third-party) |
| Compounded semaglutide (injectable)compounding program | Telehealth / compounded cash price | $197–$397 per month | Dose not published | 2026-06-01Carried over, not re-checked | $297/mo typical; $247 on a 6-month plan, $197 on 12 months. Higher doses cost more.Henry Meds review (third-party) |
| Compounded tirzepatide (injectable)telehealth programs, market range | Telehealth / compounded cash price | $199–$449 per month | Dose not published | 2026-06-01Carried over, not re-checked | Flat-rate versus dose-tiered plans; the broader reported range runs $349–$699/mo.Tirzepatide cost guide | Telehealth Ally |
| Compounded tirzepatide (injectable)compounding program, medication only | Telehealth / compounded cash price | $199 per month | $4.97 | 2026-06-01Carried over, not re-checked | Plus a $79/mo membership, $278/mo all-in; the per-mg figure is medication only, at a 10 mg weekly maintenance dose.Mochi Health review (third-party) |
| Compounded tirzepatide (injectable)compounding program | Telehealth / compounded cash price | $199 per month | Dose not published | 2026-06-01Carried over, not re-checked | Starting price; adds roughly $100/mo per dose tier above 1 mg.Henry Meds tirzepatide (third-party) |
| Compounded tirzepatide (injectable)compounding program | Telehealth / compounded cash price | $299–$399 per month | Dose not published | 2026-06-01Carried over, not re-checked | $299/mo starter, $399/mo maintenance; a microdose plan is $199/mo.Tirzepatide cost guide | Telehealth Ally |
| Compounded tirzepatide (injectable)telehealth program, medication only | Telehealth / compounded cash price | $199–$249 per month | Dose not published | 2026-06-01Carried over, not re-checked | Medication billed separately from membership.Cheapest tirzepatide providers ranked 2026 (self-published vendor ranking) |
| Compounded tirzepatide (injectable)telehealth program, annual plan | Telehealth / compounded cash price | $125 per month | Dose not published | 2026-06-01Carried over, not re-checked | Flat across doses on an annual plan. Self-published figure; treat with caution.Cheapest tirzepatide providers ranked 2026 (self-published vendor ranking) |
| Compounded semaglutide (injectable)telehealth program, annual plan | Telehealth / compounded cash price | $99 per month | Dose not published | 2026-06-01Carried over, not re-checked | Self-published figure; treat with caution.Cheapest tirzepatide providers ranked 2026 (self-published vendor ranking) |
| Ro Body membership (program fee)telehealth membership, medication separate | Telehealth / compounded cash price | $149 per month | Program fee; no drug dose | 2026-06-01Carried over, not re-checked | $39 for the first month; roughly $74/mo on annual prepay. Medication is extra.Ro weight loss pricing |
| Noom Med telehealth program (prescribing fee)telehealth membership, medication separate | Telehealth / compounded cash price | $149 per month | Program fee; no drug dose | 2026-06-01Carried over, not re-checked | Prescribing fee only. Medication is billed separately.Noom Med pricing |
Research-market compounds: no prices published yet
We have not yet run a first-party survey of research-market prices; figures from third-party buying guides are not reproduced here. Ranges will be published only after a documented survey (method, date, N).
Keep reading: browse the full Sourcing library, or start from our Fat Loss hub to see how this page fits the wider picture. For the two leading GLP-1 options head to head, see tirzepatide vs semaglutide. For what this costs in New York specifically, see peptide therapy cost in NYC.
For what this costs at a New York clinic specifically, see our NYC clinic price survey — method published, figures published when clinics give them to us.
Frequently asked questions
Related guides
Dollars per milligram compares cost, not what a compound does.
- The two research-market peptides in the table above: the BPC-157 complete guide and the TB-500 complete guide set out what is and is not established for each, and BPC-157 vs TB-500 compares them directly.
- On the GLP-1 side: tirzepatide vs semaglutide explains why the cheaper molecule per milligram is not automatically the better choice.
- If the terminology here is new: start with what peptides actually are.
What changed, and when
2026-09-30
Tirzepatide self-pay pricing was rebuilt on a source you can open, and the oral Wegovy self-pay row was confirmed. Out: both Zepbound single-dose-VIAL rows ($449/mo at 7.5 mg and at 15 mg), whose only citation — a Lilly investor release — still returns HTTP 403, as does lillydirect.lilly.com, with every alternative Lilly URL returning 403 or 404. No reachable page prices a Zepbound vial by dose, so under the rule the Ozempic wholesale-acquisition-cost withdrawal established, those figures left the page rather than sit behind a staleness flag. In: six rows for the Zepbound single-patient-use KwikPen, one per dose Lilly actually prices, from the Zepbound KwikPen Self-Pay Savings Card Program terms on a page that returns HTTP 200. Lilly states the regular 1-month self-pay price as $299 at 2.5 mg, $399 at 5 mg, $499 at 7.5 mg and $699 each at 10 mg, 12.5 mg and 15 mg, and defines the month as “28-days and up to 1 single-patient-use KwikPen” — so the four weekly doses these rows compute from are exact rather than approximate. The rows carry that regular price, not the $449 purchase offer, which is automatic on a first purchase, conditional on refilling within 45 days, and — this is the part worth stating plainly — valid only at 7.5, 10, 12.5 and 15 mg, because $299 and $399 are already below $449. Its terms state no expiry of their own; the card that carries it expires 2026-12-31. The offer is recorded in the note of each row it reaches, the same way the Wegovy self-pay row records its $199 introductory tier. The 2.5 mg row is marked not comparable because Lilly states that dose “is a starting dose and is not approved as a maintenance dose”, so its per-mg figure is a titration cost. These are the KwikPen, not the single-dose Pen, which still has no published list price, and not the vial. The net effect on the page’s prose: manufacturer self-pay now spans $11.65 to $62.38 per mg rather than $36.35 to $62.38, and the cheap end is tirzepatide again, for the same reason it is cheap at list — the maintenance dose is large. Separately, the oral Wegovy self-pay row is confirmed: NovoCare states $299 per month for the 9 mg and 25 mg tablet with one month defined as a 30-tablet bottle, exactly what the row computes from, so it carries a 2026-09-30 verification and the manufacturer as its first source. Its note also corrected a starter-dose figure — the 4 mg dose is $199, not $149.
Rows affected: zepbound-kwikpen-self-pay-2-5mg, zepbound-kwikpen-self-pay-5mg, zepbound-kwikpen-self-pay-7-5mg, zepbound-kwikpen-self-pay-10mg, zepbound-kwikpen-self-pay-12-5mg, zepbound-kwikpen-self-pay-15mg, oral-wegovy-self-pay
2026-09-16
The Ozempic wholesale-acquisition-cost row ($935.77/mo) was withdrawn. This page promises that every figure is traceable to a primary source, and that one is not: GoodRx returns the page but renders its prices in the browser, so the figure never appears in the document, and Novo Nordisk publishes no reachable pricing disclosure — every candidate URL returns 404. A number we cannot show you the source for does not belong on a price index, so it is gone rather than flagged. The Ozempic list price of $1,027.51 is unaffected and remains, confirmed against NovoCare. Tirzepatide’s wholesale acquisition cost also remains, since Lilly publishes it.
2026-09-16
Re-checked every manufacturer figure against its own source. The Wegovy self-pay row was withdrawn: Novo Nordisk lowered self-pay from $499 to $349 on 2025-11-17, and neither wegovy.com nor NovoCare shows a $499 Wegovy price today, so the row was a superseded number sitting beside the $349 that replaced it. Ozempic 2 mg self-pay ($499), Wegovy self-pay ($349), the Ozempic and Wegovy list prices, the Mounjaro wholesale acquisition cost, and the Zepbound and Rybelsus no-price findings were all re-read from the manufacturer today. Three rows could not be re-read at all — both Zepbound single-dose-vial rows and the oral Wegovy self-pay row, whose sources return HTTP 403 — and now say so instead of carrying the migration date. A fourth, the Ozempic wholesale acquisition cost, could not be sourced at all and was withdrawn; see above.
Rows affected: ozempic-pen-list, ozempic-pen-self-pay, wegovy-list, wegovy-self-pay-pharmacy-direct, mounjaro-wac-pack, zepbound-pen-no-list-price, rybelsus-no-list-price, ozempic-tablets-list, oral-wegovy-self-pay
2026-09-16
Moved from the /learn article to /prices. Every dollars-per-milligram figure is now computed from the dose inputs shown beside it rather than typed by hand, so a figure can no longer drift from the label it sits next to. Dates now record when each figure is current, not when we copied it: the Mounjaro wholesale acquisition cost is stamped January 2025 and says so.
Rows affected: ozempic-pen-list, ozempic-pen-self-pay, wegovy-list, wegovy-self-pay-pharmacy-direct, mounjaro-wac-pack, zepbound-pen-no-list-price, rybelsus-no-list-price, ozempic-tablets-list, oral-wegovy-self-pay, compounded-semaglutide-injectable-hims, compounded-semaglutide-oral-hims, compounded-semaglutide-injectable-ro, compounded-semaglutide-injectable-noom, compounded-semaglutide-mochi, compounded-semaglutide-henry, compounded-tirzepatide-market, compounded-tirzepatide-mochi, compounded-tirzepatide-henry, compounded-tirzepatide-shedrx, compounded-tirzepatide-found, compounded-tirzepatide-trimi, compounded-semaglutide-trimi, ro-body-membership-fee, noom-med-program-fee, net-price-tirzepatide, net-price-semaglutide
2026-09-16
Corrected a figure whose arithmetic did not follow from its own stated inputs. The Zepbound self-pay row printed $14.97/mg against "5 mg weekly, 20 mg/month", which computes to $19.95; the figure belongs to the 7.5 mg tier ($449 over 30 mg), and the row now carries those inputs. The same recomputation found two research-market ranges that were also wrong — BPC-157 printed as $4.50-19/mg against $38-95 per 5 mg vial, GHK-Cu as $0.59-3/mg against $30-95 per 50 mg vial — but those rows were withdrawn entirely rather than corrected; see below.
2026-09-16
Zepbound pens and Rybelsus now show no price at all. Lilly publishes no Zepbound list price, stating only that savings are capped at wholesale acquisition cost minus $499, and the NovoCare Rybelsus page returns a live page carrying zero dollar figures. Both rows record that finding instead of repeating a third-party number; the Mounjaro wholesale acquisition cost is the closest published tirzepatide benchmark.
Rows affected: zepbound-pen-no-list-price, rybelsus-no-list-price
2026-09-16
The research-market table is withheld in full. Eleven of its seventeen rows named a vendor and linked straight to that vendor’s product page; the other six were market ranges lifted from third-party buying guides. Three compounds (CJC-1295 with DAC, a CJC-1295/ipamorelin blend, and ipamorelin) existed only as storefront rows and were deleted outright. The six guide ranges were not anything Peptides.NYC measured, so republishing them under our own name would have been a methodology we did not have. Nothing replaces them until a documented first-party survey runs and can state its method, date and sample size.
References
- Ozempic® (semaglutide) injection 0.5 mg, 1 mg, 2 mg List Price & Insurance Coverage Explained | NovoCare®. Accessed 2026-09-16.
- Wegovy® (semaglutide) injection list price and coverage | NovoCare®. Accessed 2026-09-16.
- Lilly WAC disclosure (Colorado). Accessed 2026-09-16.
- Eli Lilly investor release / LillyDirect. Accessed 2026-09-16.
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Accessed 2026-09-16.
- Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. PMID: 40085108. DOI: 10.1001/jamahealthforum.2024.5586. Accessed 2026-09-16.
This page is for educational purposes only and is not medical or financial advice. Prices are snapshots; verify current pricing directly. Consult a licensed healthcare provider before any treatment decision.
Important Medical & Legal Disclaimer
Not Medical Advice: The information provided on Peptides.NYC is for educational and informational purposes only. It is not intended to be, and should not be construed as, medical advice, diagnosis, or treatment recommendations. The content creators and operators of this website are not doctors, physicians, pharmacists, or licensed medical professionals of any kind.
No Doctor-Patient Relationship: Use of this website does not create a doctor-patient or healthcare provider relationship. No information on this site should be used to diagnose, treat, cure, or prevent any disease or health condition.
Consult Healthcare Professionals: Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition, treatment, or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Research Purposes: Information about peptides, supplements, and protocols discussed on this site is presented for research and educational purposes. Many substances discussed may not be approved for human use by regulatory agencies. Any decision to use such substances is made solely at your own risk.
Assumption of Risk: By using this website, you acknowledge and agree that you assume full responsibility for any and all risks associated with acting on information presented here. The website owners, authors, and contributors shall not be held liable for any damages, injuries, or adverse effects resulting from the use or misuse of any information provided.
No Guarantees: We make no guarantees regarding the accuracy, completeness, or timeliness of any information on this site. Information may become outdated and protocols may change. Always verify information with current sources and qualified professionals.